The positive survival data in a difficult-to-treat cancer supports further development, but the small sample size (20 patients, 8 evaluable) limits statistical significance. Monitor for initiation of Phase 2b combination study and any capital needs given the company's cash position.
Price Chart
Executive Summary
Can-Fite BioPharma announced positive Phase 2a results for Namodenoson in advanced pancreatic cancer, achieving the primary safety endpoint and showing durable survival in heavily pretreated patients. Median overall survival exceeded 5 months in evaluable third-line patients, with one second-line patient alive >18 months. The company plans to advance to a Phase 2b combination study with chemotherapy.
Key Facts
- Phase 2a study (20 patients) met primary safety endpoint with Namodenoson well tolerated.
- Among 8 evaluable third-line patients, median overall survival exceeded 5 months; 62.5% survived ≥5 months, 37.5% survived ≥7 months.
- One second-line patient remains alive >18 months, the longest survivor in the study.
- Company plans to advance Namodenoson into a Phase 2b combination study with chemotherapy based on these findings and preclinical data.
Financial Impact
No financial data provided; positive clinical data may support pipeline value but company remains pre-revenue with $10M market cap.
Risk Factors
- Small sample size (20 patients, 8 evaluable in third-line) limits statistical reliability.
- Company has history of losses and may need additional capital to fund further trials.
- Early-stage data; regulatory and commercial success uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-073978 |
| Document: ea0296672-6k_canfite.htm | 0001213900-26-073978 |
| Document: 0001213900-26-073978-index-headers.html | 0001213900-26-073978 |
| Document: 0001213900-26-073978-index.html | 0001213900-26-073978 |
| Document: 0001213900-26-073978.txt | 0001213900-26-073978 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.70 (−12.82%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.70 (+12.82%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.70 (+12.82%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.70 (+26.09%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.70 (−22.37%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.70 (−27.66%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.70 (−27.97%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.70 (+27.97%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.70 (−27.97%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.70 (−52.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers